Literature DB >> 20065253

B-cell activating factor of the TNF family is upregulated in neuromyelitis optica.

Kazumasa Okada1, Takuya Matsushita, Jun-ichi Kira, Sadatoshi Tsuji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20065253     DOI： 10.1212/WNL.0b013e3181c919ee

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

Review 1.  Neuromyelitis optica: potential roles for intravenous immunoglobulin.

Authors:  Dean M Wingerchuk
Journal:  J Clin Immunol       Date:  2012-09-14       Impact factor: 8.317

2.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

3.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Wakiro Sato; Yusei Miyazaki; Sachiko Miyake; Tomoko Okamoto; Masafumi Ogawa; Tatsushi Toda; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

Review 4.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

5.  Intravenous Immunoglobulin Treatment for Recurrent Optic Neuritis.

Authors:  Burcu Altunrende; Gülden Akdal; Meltem Söylev Bajin; Aylin Yaman; Meryem Kocaslan; Mecbure Nalbantoğlu; Hülya Ertaşoğlu; Gülsen Akman
Journal:  Noro Psikiyatr Ars       Date:  2018-11-28       Impact factor: 1.339

Review 6.  B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Authors:  Jan Traub; Leila Husseini; Martin S Weber
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06

7.  Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.

Authors:  Jie Ding; Xianguo Jiang; Yu Cai; Shuting Pan; Ye Deng; Meichun Gao; Yan Lin; Nan Zhao; Ze Wang; Haojun Yu; Huiying Qiu; Yuyan Jin; Jiahui Xue; Quan Guo; Liping Ni; Ying Zhang; Yong Hao; Yangtai Guan
Journal:  CNS Neurosci Ther       Date:  2022-07-18       Impact factor: 7.035

8.  Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Shinji Oki; Takako Matsuoka; Masakazu Nakamura; Hitaru Kishida; Kazumasa Yokoyama; Yoshiyuki Kuroiwa; Nobutaka Hattori; Tomoko Okamoto; Miho Murata; Tatsushi Toda; Sachiko Miyake; Takashi Yamamura
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

9.  HMGB1/CXCL12-Mediated Immunity and Th17 Cells Might Underlie Highly Suspected Autoimmune Epilepsy in Elderly Individuals.

Authors:  Yuxiang Han; Liling Yang; Xiaoyun Liu; Yabo Feng; Zaiying Pang; Youting Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-19       Impact factor: 2.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.